Wall Street is positive on Amneal Pharmaceuticals Inc (AMRX). On average, analysts give the stock a Buy rating. The average price target is $6, which means analysts expect the stock to gain by 192.68% over the next twelve months. That average ranking earns the stock an Analyst Rating of 27, which is better than 27% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating AMRX a Buy today. Find out what this means to you and get the rest of the rankings on AMRX!